BiotechTube
Home/Pipeline/DMD Genetic Screening Panel

DMD Genetic Screening Panel

Duchenne muscular dystrophy

CommercialActive

Key Facts

Indication
Duchenne muscular dystrophy
Phase
Commercial
Status
Active
Company
Nanodigmbio

About Nanodigmbio

A Singapore‑based NGS diagnostics platform delivering ultra‑sensitive, rapid targeted sequencing solutions for oncology and infectious disease.

View full company profile

Therapeutic Areas

OncologyInfectious DiseasesGenetic DisordersHematologyImmunology

Other Duchenne muscular dystrophy Drugs

DrugCompanyPhase
MyoPAXonMyogenicaPhase 1
DMD Gene TherapyKinea BioPre-clinical
NS-051/NCNP-04NS PharmaPhase 1/2
UCT-MSC + BiomaterialsVitti LabsPhase 2
Myosana Platform for DMDMyosana TherapeuticsPre-clinical
PEPR-124 (RT-001)Peptris Technologies PrivatePhase 2-ready
KHR‑001KAHR MedicalPreclinical